This page in English

Peter Lindgren

Anknuten

Publikationer

Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study
Landfeldt E, Lindgren P, Bell Cf, Guglieri M, Straub V, Lochmüller H, et al
Developmental medicine and child neurology 2016;58(5):508-15

Assessing The Esmo Magnitude of Clinical Benefit Scale From A Health Economics Perspective
Lindgren P, Jönsson B, Wilking N
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015;18(7):A569-

Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U, Kahan T
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015;18(4):439-48

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)
Landfeldt E, Mayhew A, Eagle M, Lindgren P, Bell Cf, Guglieri M, et al
Neuromuscular disorders : NMD 2015;25(12):937-44

Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden
Journath G, Hammar N, Elofsson S, Linnersjö A, Vikström M, Walldius G, et al
PloS one 2015;10(11):e0140201-

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
Salaj P, Kubes R, Cetkovsky P, Capova I, Penka M, Ovesná P, et al
Thrombosis research 2014;133(2):162-7

Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure
Berg J, Lindgren P, Kahan T, Schill O, Persson H, Edner M, et al
JRSM cardiovascular disease 2014;3():2048004014548735-

The burden of Duchenne muscular dystrophy: an international, cross-sectional study
Landfeldt E, Lindgren P, Bell Cf, Schmitt C, Guglieri M, Straub V, et al
Neurology 2014;83(6):529-36

Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland
Nilsson J, Åkerborg Ö, Bégo-le Bagousse G, Rosenquist M, Lindgren P
The European journal of health economics : HEPAC : health economics in prevention and care 2013;14(3):481-93

Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial
Berg J, Sauriol L, Connolly S, Lindgren P
The Canadian journal of cardiology 2013;29(10):1249-55

Long term health care consumption and cost expenditure in systolic heart failure
Mejhert M, Lindgren P, Schill O, Edner M, Persson H, Kahan T
European journal of internal medicine 2013;24(3):260-5

Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland
Åkerborg Ö, Nilsson J, Bascle S, Lindgren P, Reynolds M
Clinical therapeutics 2012;34(8):1788-802

Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear Jc, Chatterton Ml
PHARMACOECONOMICS 2012;30(6):513-30

Cost-effectiveness of statins revisited: lessons learned about the value of innovation
Lindgren P, Jonsson B
EUROPEAN JOURNAL OF HEALTH ECONOMICS 2012;13(4):445-50

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
Salaj P, Penka M, Smejkal P, Geierova V, Ovesna P, Brabec P, et al
THROMBOSIS RESEARCH 2012;129(5):e233-7

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
Kasteng F, Eriksson J, Sennfalt K, Lindgren P
ACTA PSYCHIATRICA SCANDINAVICA 2011;124(3):214-25

Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries
Holstenson E, Ringborg A, Lindgren P, Coste F, Diamand F, Nieuwlaat R, et al
EUROPACE 2011;13(1):23-30

Factors determining utility measured with the EQ-5D in patients with atrial fibrillation
Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H
QUALITY OF LIFE RESEARCH 2010;19(3):381-90

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial
Ascot Trial Investigators, Lindgren P, Eriksson J, Buxton M, Kahan T, Poulter Nr, et al
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 2010;64(9):1228-34

The value of early treatment in patients with haemophilia and inhibitors
Kavakli K, Yesilipek A, Antmen B, Aksu S, Balkan C, Yilmaz D, et al
HAEMOPHILIA 2010;16(3):487-94

Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes
Ringborg A, Lindgren P, Yin Dd, Martinell M, Stalhammar J
DIABETES & METABOLISM 2010;36(3):198-203

An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
Price D, Berg J, Lindgren P
ALLERGY 2009;64(3):431-8

Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008
Atella V, Brady A, Catapano Al, Critchley J, Graham Im, Hobbs Fdr, et al
ATHEROSCLEROSIS SUPPLEMENTS 2009;10(1):3-21

Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G, Lindgren P, Geborek P
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2009;38(6):409-18

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B
CANADIAN JOURNAL OF CARDIOLOGY 2009;25(11):E362-E369

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Lindgren P, Geborek P, Kobelt G
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 2009;25(2):181-9

Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)
Ringborg A, Cropet C, Jonsson B, Gagliardino Jj, Ramachandran A, Lindgren P
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 2009;63(7):997-1007

The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden
Ringborg A, Yin Dd, Martinell M, Stalhammar J, Lindgren P
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2009;16(5):576-82

The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone Results from ASCOT
Behalf Ascot Investigators, Lindgren P, Buxton M, Kahan T, Poulter Nr, Dahlof B, et al
PHARMACOECONOMICS 2009;27(3):221-30

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions
Kobelt G, Texier-richard B, Lindgren P
MULTIPLE SCLEROSIS 2009;15(6):741-51

Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials
Berg J, Fidan D, Lindgren P
CURRENT MEDICAL RESEARCH AND OPINION 2008;24(7):2089-101

Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation
Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni Ap, et al
EUROPACE 2008;10(4):403-11

Economic evaluation of FENO measurement in diagnosis and 1-year management of asthma in Germany
Berg J, Lindgren P
RESPIRATORY MEDICINE 2008;102(2):219-31

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J
MULTIPLE SCLEROSIS 2008;14(5):679-90

Prevalence and incidence of Type 2 diabetes and its complications 1996-2003 - estimates from a Swedish population-based study
Ringborg A, Lindgren P, Martinell M, Yin Dd, Schon S, Stalhammar J
DIABETIC MEDICINE 2008;25(10):1178-86

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data
Ringborg A, Martinell M, Stalhammar J, Yin Dd, Lindgren P
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 2008;62(5):708-16

Utility loss and indirect costs after stroke in Sweden
Lindgren P, Glader El, Jonsson B
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2008;15(2):230-3

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials
Berg J, Lindgren P, Spiesser J, Parry D, Jonsson B
CLINICAL THERAPEUTICS 2007;29(6):1184-202

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Ideal Trial Investigators, Lindgren P, Graff J, Olsson Ag, Pedersen Tj, Jonsson B
EUROPEAN HEART JOURNAL 2007;28(12):1448-53

Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs
Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Jonsson L
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 2007;61(8):1410-4

Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective
Dps Study Grp, Lindgren P, Lindstrom J, Tuomilehto J, Uusitupa M, Peltonen M, et al
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 2007;23(2):177-83

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
Bruggenjurgen B, Lindgren P, Ehlken B, Rupprecht Hj, Willich Sn
EUROPEAN JOURNAL OF HEALTH ECONOMICS 2007;8(1):51-7

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
Ascot Investigators, Lindgren P, Kahan T, Poulter N, Buxton M, Svarvar P, et al
EUROPEAN JOURNAL OF HEALTH ECONOMICS 2007;8(1):25-30

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
Kobelt G, Berg J, Lindgren P, Jönsson B
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S5-13

Costs and quality of life in multiple sclerosis in The Netherlands
Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen Pj, et al
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S55-64

Costs and quality of life of multiple sclerosis in Austria
Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, et al
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S14-23

Costs and quality of life of multiple sclerosis in Germany
Kobelt G, Berg J, Lindgren P, Elias Wg, Flachenecker P, Freidel M, et al
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S34-44

Costs and quality of life of multiple sclerosis in Italy
Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S45-54

Costs and quality of life of multiple sclerosis in Spain
Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-soliño O, Pérez-miranda J, et al
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S65-74

Costs and quality of life of multiple sclerosis in Sweden
Berg J, Lindgren P, Fredrikson S, Kobelt G
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S75-85

Costs and quality of life of multiple sclerosis in Switzerland
Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S86-95

Costs and quality of life of multiple sclerosis in the United Kingdom
Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S96-104

Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 2006;77(8):918-26

Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin Ddp, Jonsson L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2005;12(6):530-4

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
Ascot Investigators, Lindgren P, Buxton M, Kahan T, Poulter Nr, Dahlof B, et al
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2005;12(1):29-36

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
Kobelt G, Lindgren P, Singh A, Klareskog L
ANNALS OF THE RHEUMATIC DISEASES 2005;64(8):1174-9

Cost of Parkinson's disease in Europe
Lindgren P, Von Campenhausen S, Spottke E, Siebert U, Dodel R
EUROPEAN JOURNAL OF NEUROLOGY 2005;:68-73

Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K
RHEUMATOLOGY 2005;44(9):1169-75

The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial
Ringborg A, Lindgren P, Jönsson B
The European journal of health economics : HEPAC : health economics in prevention and care 2005;6(4):354-6

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
Lindgren P, Stenestrand U, Malmberg K, Jonsson B
CLINICAL THERAPEUTICS 2005;27(1):100-10

Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial
Lindgren P, Jonsson B, Yusuf S
JOURNAL OF INTERNAL MEDICINE 2004;255(5):562-70

The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study
Cure Ec Grp, Lamy A, Jonsson B, Weintraub Ws, Zhao F, Chrolavicius S, et al
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2004;11(6):460-5

Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm - a stochastic model of exercise and dietary advice
Lindgren P, Fahlstadius P, Hellenius Ml, Jonsson B, De Faire U
PREVENTIVE MEDICINE 2003;36(4):403-9

The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden
Lindgren P, Jönsson B, Duchane J
The European journal of health economics : HEPAC : health economics in prevention and care 2003;4(1):37-42

Cost-effectiveness analysis of exemestane compared with Megestrol in advanced breast cancer - A model for Europe and Australia
Lindgren P, Jonsson B, Redaelli A, Radice D
PHARMACOECONOMICS 2002;20(2):101-8

Modeling the progression of rheumatoid arthritis - A two-country model to estimate costs and consequences of rheumatoid arthritis
Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K
ARTHRITIS AND RHEUMATISM 2002;46(9):2310-9

Costs of mini mental state examination-related cognitive impairment
Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B
PHARMACOECONOMICS 1999;16(4):409-16

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model
Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B
CLINICAL THERAPEUTICS 1999;21(7):1230-40

Visa alla publikationer

Karta